Jump to content

Crystalline Arthritis

Original Editor - Yasmin Maraya S Verzosa
Top Contributors - Yasmin Maraya S Verzosa and Kim Jackson

Overview

Crystalline Arthritis, collective term used for crystal depositions in the joints and often in soft tissues. In primary care, it is one of the most common musculoskeletal conditions.[1] Arthritis, in different stages can be acute, chronic or asymptomatic; In Crystal Arthropathies, this type of arthritis is due to several types of crystals that accumulated in joints and other soft tissues.[2]

The three main types of crystal arthritis:

  • Gout - Monosodium urate (MSU)
  • Calcium pyrophosphate (dihydrate) deposition disease (CPPD)
    • Pseudogout or Chondrocalcinosis[3]
  • Hydroxyapatite deposition disease (HADD)[4]
    • Calcium hydroxyapatite (CHA)
    • Basic calcium phosphate crystal deposition disease[5]



Clinically Relevant Anatomy

Joints
First Metatarsophalangeal Joint The big toe is most commonly affected (gout or podagra).[6]
Knees Commonly affected in CPPD and also seen in gout.[7]
Ankles Frequently involved in gout attacks.[8]
Shoulders Seen in Milwaukee shoulder syndrome, a type of chronic destructive arthropathy, It usually affects older women that develops in the shoulders.[5]
Wrists Commonly affected in CPPD and sometimes in gout.[9]
Elbows Olecranon bursa can be involved in gout.[10]
Digits Particularly the small joints (interphalangeal joints) and wrist, often affected in CPPD and sometimes in gout.[11]
Soft Tissues and Cartilages
Synovium The joint lining is inflammed due to crystal deposition.[12]
Tendons and Tendon Sheaths Can be involved in chronic gout leading to tophi formation.[13]
Bursae The olecranon and prepatellar bursae can be involved, particularly in gout.[14]
Specific Structures
Tophi MSU deposits commonly found in chronic gout, usally in the ears, fingers, elbows, and Achilles tendon.[12]
Chondrocalcinosis Calcification seen in cartilages, indicative of CPPD, particularly in the knees and wrists.[7]
Periarticular Tissues Inflammation and pain can extend to the tissues surrounding the affected joints.[14]

Aetiology

The aetiology of Crystalline Arthritis is usually multifactorial, this includes— genetic predisposition, medical comorbidities, and nutrition/dietary habits of a patient. In rare instances, a single genetic defect may be the cause of these type of conditions, often linked with other medical complications. Regardless of the underlying cause, the laboratory results indicate elevated serum uric acid, which can manifest as clinical gout in some individuals..[15]

Pseudogout, characterized by calcium pyrophosphate (CPP) deposition disease, is thought to result from an imbalance between pyrophosphate production and pyrophosphatase levels in affected soft tissues like cartilages. When pyrophosphate accumulates in the synovium and surrounding tissues, it combines with calcium to form CPP crystals..[16]

These ultramicroscopic crystals, which appear in snowball-like clumps, are found in various rheumatic conditions such as calcific tendinitis, calcific periarthritis, and some cases of progressive systemic sclerosis and dermatomyositis. Additionally, they are present in the synovium and cartilages of patients with advanced degenerative arthropathies that cause joint space narrowing visible on x-ray.[5]

HADD encompasses a range of conditions, including calcific tendinitis, other periarticular hydroxyapatite deposits, and hydroxyapatite-induced arthritis.[17][18] Other terns used for HADD are calcific tendinosis, peritendinitis calcarea, calcific peritendinitis and bursitis, and hydroxyapatite rheumatism.[19] CHA is the most common type of calcium found in the human bone and is the most frequently encountered type of pathological calcification in the body..[20]

Pathology

CPPD crystals seen under polarizing light microscopy. These crystals appear as weakly positive birefringent rhomboidal crystals.[21]

Acute articular inflammation is the hallmark of crystal-induced arthritis, albeit joint damage or long-term impairment are uncommon outcomes. It was determined that crystals can induce arthritis when MSU crystals were found in patients with joint effusions of gouty arthritis. Additional crystals that have been linked to arthritis include CHA crystals (calcific periarthritis, acute arthritis), CPPD crystals (chondrocalcinosis, pseudo-gout), and deposition of corticosteroid crystals (which can occasionally cause arthritis when injected intra-articularly).[22]

Crystal-induced arthritis can be diagnosed by either extracellular or seen as white blood cell-engulfed crystals. The risk of concurrent infections or other inflammatory forms of arthritis does not disappear in the presence of crystals. BCP crystals have the potential to severely inflame the periarticular space or joints..[5]


Clinical Presentation

Gouty tophi on the elbow of a middle-aged male nurse.

The clinical manifestations of crystal arthritis types are frequently distinctive enough to set them apart from other inflammatory arthropathies and from one another. Nevertheless, diagnostic errors may occur, resulting in improper or delayed treatment. MSU crystal precipitation is the primary cause of gout which is the most prevalent crystal arthropathy. Inflammatory symptoms resulting from crystal deposition in and around joints are also linked to two other important forms of crystals, (1) basic calcium phosphate crystal (hydroxyapatite), also called HADD and (2) CPPD, which causes pseudogout.[23]

Gout
  • Intense pain on affected area
  • Tenderness, even with a light touch
  • Swelling
  • Stiffness
  • Discolouration or redness
  • Warmth, giving a sensation as if the joint is “on fire”
CPPD
  • Sudden, intense joint pain
  • Skin discolouration or redness
  • Swelling
  • Stiffness
  • A feeling of heat or warmth in or around a joint
HADD
  • Acute onset of significant joint pain
  • Swelling
  • Tenderness
  • Inflammation
  • Decreased mobility in the affected joint

Diagnostic Procedures

Radiographic chondrocalcinosis. Dense deposits of CPPD are seen in this knee radiograph in the fibrocartilage of the meniscus.[21]

Synovial Fluid Analysis

  • For the diagnosis of gout, MSU crystal identification is still considered the gold standard. A gout flare-up is identified by the observation of MSU crystals in the synovium that have been damaged, utilizing compensated polarized light microscopy.[24]

Laboratory Study

  • The results often presents with WBC elevation, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) during acute gouty arthritis. These results are nonspecific and do not confirm nor differentiate the diagnosis of gout from septic arthritis.[25]
Radiographic chondrocalcinosis. Dense deposits of CPPD are seen outlining the contours of the articular cartilage in this knee radiograph.[21]

Imaging

  • Plain radiographs and ultrasonography scans show if there are any crystals in the affected joints and soft tissues, as well as excess synovial fluid in the joint, or there is an existing joint damage already. Sometimes, advanced imaging such as computed tomography (CT) and magnetic resonance imaging (MRI) may also be used to detect the presence of crystal deposition.[26][21]


Outcome Measures

Management / Interventions

CPPD Treatment

It is not possible to fully resolve or arrest the development of calcium pyrophosphate (CPP) dihydrate crystals. Nonetheless, treatment usually result in the resolution of joint discomfort and edema. The type of crystal deposition determines the appropriate intervention, which may include but are not limited to the following:[26]

  • Immobilisation: Patients experiencing a flare may be advised to avoid weight-bearing activities, such as walking or running if the lower extremities are involved. Excessive movement and strenuous activities should also be limited to minimize pain and swelling. In some cases, a temporary splint may be recommended to restrict joint movement.
  • Aspiration and/or Injection: If one or two joints are affected during the acute phase, joint aspiration and/or injection would likely be the preferred treatment option. To further reduce pain and release pressure in the affected joint, fluid and crystals from the damaged joint are aspirated by a medical doctor. To lessen inflammation, the attending physician may use glucocorticoid (steroidal) injections.
  • Pharmacologic treatment:
    • Oral anti-inflammatory medications is an option to prevent attacks of acute phase and manage chronic phase, physicians prescribe nonsteroidal anti-inflammatory drugs (NSAIDs), oral glucocorticoids, or colchicine may be preferred over joint injections. Usually, these medications are continued until the flare resolves.
    • Immunosuppressive drugs are also prescribed to further lessen inflammation by suppressing the immune system, patients with acute or chronic phases may occasionally need to take immunosuppressive medications. For example, patients experiencing significant flare-ups in acute phase may be administered with disease-modifying antirheumatic drugs (DMARDs) such as canakinumab (Ilaris) or anakinra (Kineret), particularly if they are not responding to other interventions or cannot tolerate other medications.
Icing on the ankle joint.


Patient education
is essential in order to manage symptoms and avoid flare-ups. Patients should be made aware of the importance of maintaining enough hydration, as this can potentially lessen the frequency of flares by lowering the body's uric acid or calcium pyrophosphate. Furthermore, educating patients about lifestyle and dietary changes—such as cutting back on food high in purines if they have gout or keeping a balanced diet to control calcium levels—can make a big difference in the patient's overall wellbeing.[27][28]

Heat and cold modalities such as hot compress and icing, may alleviate pain; Physical Therapy is also an intervention to aid in strengthening and increasing the flexibility in the muscles and soft tissues around the joints, which could also be beneficial for the patient.[21]

According to PU Farin, et al, "Recalcitrant CHA deposits can be removed surgically or with image-guided aspiration." [29]

Summary

  • Crystalline arthritis is caused by the deposition of crystals in the joints.
  • The two main types are gout (MSU crystals) and pseudogout (CPPD).
    • Another type is basic calcium phosphate crystal deposition disease (HADD).
  • Symptoms of these type of arthritis include sudden, severe pain, swelling, and discolouration/redness in the affected joint.
    • One or more joints may be affected in an acute (flare-up) or chronic phase.
  • Diagnosis is confirmed through synovial fluid analysis, imaging, and laboratory tests.
  • Treatment typically involves pain relief, oral anti-inflammatory medications, aspiration/injection, and lifestyle changes.
  • Preventive measures include patient education, dietary modifications, and adequate hydration.
  • Crystalline arthritis can lead to joint damage if left untreated.
  • Early detection and intervention is necessary for managing symptoms effectively.

References

  1. ↑ Baquir P, Yoon J, Cai K. Crystal arthritis: Managing gout and calcium pyrophosphate deposition disease. Medicine Today. 2024 Apr. Available from: https://medicinetoday.com.au/mt/2024/april/feature-article/crystal-arthritis-managing-gout-and-calcium-pyrophosphate-deposition-disease
  2. ↑ Hall S. Crystal arthritis: a clinician's view. Aust Fam Physician. 1991 Dec;20(12):1717-24. PMID: 1805773. Available from: https://pubmed.ncbi.nlm.nih.gov/1805773/
  3. ↑ Morrison WB, Sanders TG, editors. Problem Solving in Musculoskeletal Imaging. Philadelphia: Saunders; 2024. 560 p. ISBN: 978-0-323-04034-1 Available from: https://www.researchgate.net/publication/246335019_WB_Morrison_and_TG_Sanders_Problem_Solving_in_Musculoskeletal_Imaging_Mosby_2008_ISBN_978-0-323-04034-1_pages_775_prize_Euro_10444
  4. ↑ Quinn S. Hydroxyapatite Deposition Disease. Radsource [Internet]. [cited 2024 Sep 20]. Available from: https://radsource.us/hydroxyapatite-deposition-disease/
  5. ↑ 5.0 5.1 5.2 5.3 Keller SF. Overview of Crystal-Induced Arthritides. In: MSD Manual Professional Edition [Internet]. Jul 2022 [cited 2024 Sep 20]. Available from: https://www.msdmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/crystal-induced-arthritides/overview-of-crystal-induced-arthritides
  6. ↑ Terkeltaub R. Gout. N Engl J Med. 2003 Jan 23;348(1):27-38. Available from: https://pubmed.ncbi.nlm.nih.gov/14573737/
  7. ↑ 7.0 7.1 Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016 Dec 22;375(25):2575-2584. Accessed from: https://pubmed.ncbi.nlm.nih.gov/27355536/
  8. ↑ Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020 Jan;79(1):31-38. Accessed from: https://pubmed.ncbi.nlm.nih.gov/31167758/
  9. ↑ Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: Management. Ann Rheum Dis. 2011 May. Accessed from: https://pubmed.ncbi.nlm.nih.gov/21216817/
  10. ↑ Perez-Ruiz F, Dalbeth N. Evidence reviews for urate-lowering therapies for the long-term management of gout Ther Adv Chronic Dis. 2015 May;6(3):92-101. Accessed from: https://www.ncbi.nlm.nih.gov/books/NBK589579/
  11. ↑ Olmez N, Schumacher HR Jr. Crystal deposition and osteoarthritis. Curr Rheumatol Rep. 1999 Dec;1(2):107-11. doi: 10.1007/s11926-999-0006-4. PMID: 11123023. Accessed from: https://pubmed.ncbi.nlm.nih.gov/11123023/
  12. ↑ 12.0 12.1 Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016 Jan 23;387(10026):1843-1855. Accessed from: https://pubmed.ncbi.nlm.nih.gov/27112094/
  13. ↑ Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004 Aug;31(8):1582-7. PMID: 15290739. Accessed from: https://pubmed.ncbi.nlm.nih.gov/15290739/
  14. ↑ 14.0 14.1 Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs. 2004;64(21):2399-2416. Accessed from: https://pubmed.ncbi.nlm.nih.gov/15481999/
  15. ↑ Fenando A, Rednam M, Gujarathi R, et al. Gout. [Updated 2024 Feb 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK546606/
  16. ↑ Higgins PA. Gout and pseudogout. JAAPA. 2016 Mar;29(3):50-2. doi: 10.1097/01.JAA.0000475472.40251.58. PMID: 26914781. https://pubmed.ncbi.nlm.nih.gov/26914781/
  17. ↑ Bonavita JA, Dalinka MK, Schumacher HR, Jr. Hydroxyapatite deposition disease. Radiology 1980; 134:621-625. Accessed from: https://radsource.us/hydroxyapatite-deposition-disease/
  18. ↑ Resnick D. Calcium hydroxyapatite crystal deposition disease. In: Resnick D, Niawayama G, eds. Diagnosis of bone and joint disorders. 2nd ed. Philadelphia: Saunders, 1988; 1733-1764. Accessed from: https://pubs.rsna.org/doi/abs/10.1148/radiographics.10.6.2175444?journalCode=radiographics
  19. ↑ Molloy ES, McCarthy GM. Calcium crystal deposition diseases: update on pathogenesis and manifestations. Rheum Dis Clin North Am 2006; 32:383-400, vii. Accessed from: https://www.sciencedirect.com/science/article/abs/pii/S0889857X06000184?via%3Dihub
  20. ↑ Hayes CW, Conway WF. Calcium hydroxyapatite deposition disease. Radiographics 1990; 10:1031-1048. https://pubmed.ncbi.nlm.nih.gov/2175444/
  21. ↑ 21.0 21.1 21.2 21.3 21.4 Rosenthal AK, Ryan LM. Nonpharmacologic and pharmacologic management of CPP crystal arthritis and BCP arthropathy and periarticular syndromes. Rheum Dis Clin North Am. 2014 May;40(2):343-56. doi: 10.1016/j.rdc.2014.01.010. Epub 2014 Feb 19. PMID: 24703351; PMCID: PMC6240445. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240445/
  22. ↑ Reginato A, Paul H, Schumacher HR. Crystal-induced arthritis. Archives of Physical Medicine and Rehabilitation. 1982 Sep;63(9):401-408. PMID: 6287963. https://pubmed.ncbi.nlm.nih.gov/6287963/
  23. ↑ Tan SYW, Stanway J, Ellis S. Crystal arthropathies. Medicine. 2022;50(2):109-115. doi:10.1016/j.mpmed.2021.11.008. Available from: https://www.sciencedirect.com/science/article/pii/S1357303921003200
  24. ↑ Fenando A, Widrich J. Gout (podagra). Available: https://www.ncbi.nlm.nih.gov/books/NBK546606/ (accessed 20.9.2024)
  25. ↑ Coakley G, Mathews C, Field M, Jones A, Kingsley G, Walker D, Phillips M, Bradish C, McLachlan A, Mohammed R, Weston V., British Society for Rheumatology Standards, Guidelines and Audit Working Group. BSR & BHPR, BOA, RCGP and BSAC guidelines for management of the hot swollen joint in adults. Rheumatology (Oxford). 2006 Aug;45(8):1039-41
  26. ↑ 26.0 26.1 Rosenthal AK. Patient education: Calcium pyrophosphate crystal deposition (CPPD) disease (Beyond the Basics). In: Dalbeth N, Case SM, editors. UpToDate [Internet]. Available from: https://www.uptodate.com/contents/calcium-pyrophosphate-crystal-deposition-cppd-disease-beyond-the-basics
  27. ↑ Fenando A, Rednam M, Gujarathi R, et al. Gout. [Updated 2024 Feb 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK546606/
  28. ↑ Yokose C, McCormick N, Choi HK. The role of diet in hyperuricemia and gout. Curr Opin Rheumatol. 2021 Mar 1;33(2):135-144. doi: 10.1097/BOR.0000000000000779. PMID: 33399399; PMCID: PMC7886025. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886025/
  29. ↑ Farin PU, Rasanen H, Jaroma H, Harju A. Rotator cuff calcifications: treatment with ultrasound-guided percutaneous needle aspiration and lavage. Skeletal Radiol 1996; 25:551-554. Accessed from: https://pubmed.ncbi.nlm.nih.gov/8865489/